23874253 2013 07 22 2013 07 22 2013 07 24

1556-3316 8 2 2012 Jul HSS J Regional anesthesia for children undergoing orthopedic ambulatory surgeries in the United States, 1996-2006. 133-6 10.1007/s11420-012-9278-8 Our objective was to evaluate national trends in regional anesthetic techniques among children undergoing ambulatory orthopedic procedures. We aimed to determine whether an increase in regional anesthetics was primarily driven by an increase in the number of peripheral nerve blocks performed rather than an increase in neuraxial techniques. We further aimed to determine whether the proportion of peripheral nerve blocks performed in conjunction with general anesthesia has increased over time. Our study sample included any pediatric patient (i.e., <18 years old) who underwent an orthopedic ambulatory procedure in 1996 and 2006. We obtained data on ambulatory surgical procedures by accessing the Centers for Disease Control and Prevention's National Survey of Ambulatory Surgery. Patient demographics (age, gender), procedure information, and anesthesia-related variables were analyzed for each year. The proportion of peripheral nerve blocks performed for ambulatory surgery more than doubled from 1996 (4.4 %) to 2006 (8.1 %). A significantly larger proportion of orthopedic procedures were being performed with a combination of peripheral nerve blocks and general anesthesia (1.2 % in 1996 and 43 % 2006). The use of neuraxial anesthesia for lower extremity surgeries decreased over the 10-year period (1.1 and 0.4 % in 1996 and 2006, respectively). There was a significant increase in the use of peripheral nerve blocks for children undergoing ambulatory orthopedic procedures in the USA, while neuraxial techniques became less common over the 10-year period. The peripheral nerve blocks were frequently performed in conjunction with general anesthesia. Kuo Cassie C Department of Anesthesiology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA. Edwards Alison A Mazumdar Madhu M Memtsoudis Stavros G SG eng Journal Article 2012 06 20

United States HSS J 101273938 1556-3316 PMC3715624 ambulatory surgery pediatrics regional anesthesia 2012 1 15 2012 4 16 2012 6 20 2013 7 23 6 0 2013 7 23 6 0 2013 7 23 6 1 ppublish 10.1007/s11420-012-9278-8 9278 23874253 PMC3715624 23194934 2013 03 04 2014 01 14 2014 03 28

1545-7206 54 2 2013 Mar-Apr Psychosomatics Demographics and perioperative outcome in patients with depression and anxiety undergoing total joint arthroplasty: a population-based study. 149-57 10.1016/j.psym.2012.08.009 S0033-3182(12)00159-4 Depression and anxiety are highly prevalent psychiatric disorders. However, little is known about their impact on outcomes in the perioperative setting. This study is intended to gain insight into epidemiology and effects on perioperative morbidity, mortality, length of hospital stay, discharge and cost. We obtained the National Inpatient Sample from the Hospital Cost and Utilization Project for each year between 2000 and 2008. Entries indicating the performance of primary total hip and knee arthroplasty were identified and separated into four groups: (1) those with concomitant diagnosis of depression or (2) anxiety, (3) both, and (4) none of these diagnoses. The incidence of major complications, non-routine discharge, length, and cost of hospitalization were assessed. Regression analysis was performed to identify if psychiatric comorbidity was an independent risk factor for each outcome. We identified 1,212,493 patients undergoing arthroplasty between 2000 and 2008. The prevalence of depression and anxiety significantly increased over time. Patients with either condition had higher hospital charges, rates of non-routine discharges and comorbidity index. Depression or anxiety were associated with significantly decreased adjusted odds for in-hospital mortality (OR = 0.53, p = 0.0147; OR = 0.58, p = 0.0064). The risk of developing a major complication was slightly lower in patients with depression, anxiety or both (OR=0.95, p = 0.0738; OR = 0.95, p = 0.0259; OR = 0.94, p = 0.7349). Patients suffering from depression, anxiety, or both require more healthcare resources in a perioperative setting. However, lower short-term mortality in spite of higher comorbidity burden and without extensive changes in perioperative complication profile indicates better outcome for this group of patients. Copyright © 2013 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved. Stundner Ottokar O Department of Anesthesiology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA. Kirksey Meghan M Chiu Ya Lin YL Mazumdar Madhu M Poultsides Lazaros L Gerner Peter P Memtsoudis Stavros G SG eng U18 HS016-75 HS AHRQ HHS United States UL1 RR024996 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. 2012 11 27

England Psychosomatics 0376506 0033-3182 IM Adult Aged Analysis of Variance Anxiety Disorders economics epidemiology Arthroplasty, Replacement adverse effects psychology statistics & numerical data Comorbidity Demography Depressive Disorder economics epidemiology Female Hospital Mortality Hospitalization economics statistics & numerical data Humans Logistic Models Male Middle Aged Odds Ratio Outcome Assessment (Health Care) economics statistics & numerical data Perioperative Period economics statistics & numerical data Postoperative Complications epidemiology Prevalence United States epidemiology 2012 7 16 2012 8 17 2012 8 20 2012 11 27 2012 12 1 6 0 2012 12 1 6 0 2014 1 15 6 0 ppublish S0033-3182(12)00159-4 10.1016/j.psym.2012.08.009 23194934 23091119 2012 10 23 2013 01 03 2013 11 14

1524-4628 43 11 2012 Nov Stroke Cerebrovascular reserve and stroke risk in patients with carotid stenosis or occlusion: a systematic review and meta-analysis. 2884-91 10.1161/STROKEAHA.112.663716 Impairments in cerebrovascular reserve (CVR) have been variably associated with increased risk of ischemic events and may stratify stroke risk in patients with high-grade internal carotid artery stenosis or occlusion. The purpose of this study is to perform a systematic review and meta-analysis to summarize the association of CVR impairment and stroke risk. We performed a literature search evaluating the association of impairments in CVR with future stroke or transient ischemic attack in patients with high-grade internal carotid artery stenosis or occlusion. We included studies with a minimum of 1-year patient follow-up with baseline CVR measures performed by any modality and primary outcome measures of stroke and/or transient ischemic attack. A meta-analysis with assessment of study heterogeneity and publication bias was performed. Results were presented in a forest plot and summarized using a random-effects model. Thirteen studies met the inclusion criteria, representing a total of 1061 independent CVR tests in 991 unique patients with a mean follow-up of 32.7 months. We found a significant positive relationship between impairment of CVR and development of stroke with a pooled random effects OR of 3.86 (95% CI, 1.99-7.48). Subset analysis showed that this association between CVR impairment and future risk of stroke/transient ischemic attack remained significant regardless of ischemic outcome measure, symptomatic or asymptomatic disease, stenosis or occlusion, or CVR testing method. CVR impairment is strongly associated with increased risk of ischemic events in carotid stenosis or occlusion and may be useful for stroke risk stratification. Gupta Ajay A Department of Radiology, Weill Cornell Medical School, New York-Presbyterian Hospital, 525 East 68th Street, Starr 8A, Box 141, New York, NY 10065, USA. ajg9004@med.cornell.edu Chazen J Levi JL Hartman Maya M Delgado Diana D Anumula Nikesh N Shao Huibo H Mazumdar Madhu M Segal Alan Z AZ Kamel Hooman H Leifer Dana D Sanelli Pina C PC eng RFA-HS-05-14 HS AHRQ HHS United States UL1 TR000457 TR NCATS NIH HHS United States UL1 TR000457 TR NCATS NIH HHS United States Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

United States Stroke 0235266 0039-2499 IM Brain. 2001 Mar;124(Pt 3):457-67 11222446 JAMA. 2011 Nov 9;306(18):1983-92 22068990 J Cereb Blood Flow Metab. 2002 Sep;22(9):1142-8 12218420 Lancet. 2004 May 8;363(9420):1491-502 15135594 Stroke. 2004 Aug;35(8):e349-52 15232124 Control Clin Trials. 1986 Sep;7(3):177-88 3802833 Stroke. 2001 Sep;32(9):2110-6 11546904 JAMA. 2000 Apr 26;283(16):2122-7 10791504 N Engl J Med. 1991 Aug 15;325(7):445-53 1852179 Stroke. 1992 Feb;23(2):171-4 1561643 J Vasc Surg. 1995 Feb;21(2):338-44; discussion 344-5 7853605 Stroke. 1996 Dec;27(12):2188-90 8969778 Stroke. 1997 Oct;28(10):2084-93 9341723 Stroke. 1999 Mar;30(3):593-8 10066857 Neurology. 2005 Sep 27;65(6):794-801 16186516 Int Angiol. 2006 Dec;25(4):385-8 17164745 Stroke. 2008 May;39(5):1647-52 18322260 J Neurol. 2008 Aug;255(8):1182-9 18575926 PLoS Med. 2009 Jul 21;6(7):e1000100 19621070 Ann Nucl Med. 2010 Jun;24(5):371-7 20238185 Eur J Neurol. 2010 Oct;17(10):1285-90 20374276 Stroke. 2011 Jun;42(6):1550-5 21527764 Stroke. 2013 Oct;44(10):e137 Brain blood supply Carotid Stenosis complications Cerebrovascular Circulation Cerebrovascular Disorders complications Humans Risk Factors Stroke etiology NIHMS409686 PMC3500140 2012 10 24 6 0 2012 10 24 6 0 2013 1 4 6 0 ppublish 43/11/2884 10.1161/STROKEAHA.112.663716 23091119 PMC3500140 NIHMS409686 23080348 2012 10 24 2013 04 08 2013 11 14

1532-8651 37 6 2012 Nov-Dec Reg Anesth Pain Med Comparative perioperative outcomes associated with neuraxial versus general anesthesia for simultaneous bilateral total knee arthroplasty. 638-44 10.1097/AAP.0b013e31826e1494 The influence of the type of anesthesia on perioperative outcomes after bilateral total knee arthroplasty (BTKA) remains unknown. Therefore, we examined a large sample of BTKA recipients, hypothesizing that neuraxial anesthesia would favorably impact on outcomes. We identified patient entries indicating elective BTKA between 2006 and 2010 in a national database; subgrouped them by type of anesthesia: general (G), neuraxial (N), or combined neuraxial-general (NG); and analyzed differences in demographics and perioperative outcomes. Of 15,687 identified procedures, 6.8% (n = 1066) were performed under N, 80.1% (n = 12,567) under G, and 13.1% (n = 2054) under NG. Comparing N to G and NG, patients in group N were, on average, younger (63.9, 64.6, and 64.8 years; P = 0.030) but did not differ in overall comorbidity burden. Patients in group N required blood product transfusions significantly less frequently (28.5%, 44.7%, 38.0%; P < 0.0001). In-hospital mortality, 30-day mortality, and complication rates tended to be lower in group N, without reaching statistical significance. After adjusting for covariates, N and NG were associated with 16.0% and 6.0% reduction in major complications compared with G, but only the reduced odds for the requirement of blood transfusions associated with N reached statistical significance (N vs G: odds ratio, 0.52 [95% CI, 0.45-0.61], P < 0.0001; NG vs G: odds ratio, 0.77 [95% CI, 0.69-0.86], P < 0.0001). Neuraxial anesthesia for BTKA is associated with significantly lower rates of blood transfusions and, by trend, decreased morbidity. Although by itself the effect may be limited, N might be used within a multimodal approach to reduce complications after BTKA. Stundner Ottokar O Department of Anesthesiology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA. Chiu Ya-Lin YL Sun Xuming X Mazumdar Madhu M Fleischut Peter P Poultsides Lazaros L Gerner Peter P Fritsch Gerhard G Memtsoudis Stavros G SG eng U18 HSO16-75 PHS HHS United States UL1 RR024996 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

United States Reg Anesth Pain Med 9804508 1098-7339 IM Anesth Analg. 2006 Oct;103(4):1018-25 17000823 Adv Ther. 2006 Jan-Feb;23(1):54-67 16644607 Lancet. 2008 Aug 16;372(9638):562-9 18692893 Clin Orthop Relat Res. 2008 Nov;466(11):2617-27 18704616 Clin Orthop Relat Res. 2009 Jun;467(6):1568-76 19002540 J Bone Joint Surg Br. 2009 Jul;91(7):935-42 19567860 Anesthesiology. 2009 Dec;111(6):1206-16 19934863 JAMA. 2010 Jun 23;303(24):2479-85 20571014 J Knee Surg. 2011 Mar;24(1):25-31 21618935 J Orthop Surg Res. 2011;6:22 21600028 Anesth Analg. 2011 Oct;113(4):784-90 21752942 Am J Epidemiol. 2012 Feb 1;175(3):210-7 22262640 J Orthop Sci. 2012 Jul;17(4):432-6 22476426 J Bone Joint Surg Am. 2012 Dec 5;94(23):2120-7 23097096 BMJ. 2000 Dec 16;321(7275):1493 11118174 J Bone Joint Surg Am. 2001 Aug;83-A(8):1157-61 11507123 Anesth Analg. 2002 Jun;94(6):1441-7 12032003 J Clin Anesth. 2003 Sep;15(6):433-40 14652120 Clin Orthop Relat Res. 1991 Aug;(269):109-12 1864027 J Clin Epidemiol. 1992 Jun;45(6):613-9 1607900 J Bone Joint Surg Br. 1991 May;73(3):418-22 1670442 Biomed Sci Instrum. 1997;33:429-34 9731398 N Engl J Med. 2005 Jul 28;353(4):349-61 16049209 J Clin Anesth. 2006 Mar;18(2):124-8 16563330 J Knee Surg. 2006 Oct;19(4):249-53 17080646 Adult Age Distribution Aged Anesthesia, Epidural Anesthesia, General Anesthesia, Spinal Arthroplasty, Replacement, Knee Blood Transfusion utilization Databases, Factual Female Hospital Mortality Humans Length of Stay statistics & numerical data Male Middle Aged Multivariate Analysis Postoperative Complications epidemiology Respiration, Artificial statistics & numerical data NIHMS462726 PMC3653590 2012 10 20 6 0 2012 10 20 6 0 2013 4 9 6 0 ppublish 10.1097/AAP.0b013e31826e1494 23080348 PMC3653590 NIHMS462726 23068970 2013 01 14 2013 07 01 2014 03 28

1532-2688 22 1 2013 Jan Seizure Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis. 3-8 10.1016/j.seizure.2012.09.014 S1059-1311(12)00256-7 Lennox-Gastaut syndrome (LGS) is an epileptogenic disorder that arises in childhood and is typically characterized by multiple seizure types, slow spike-and-wave complexes on EEG and cognitive impairment. If medical treatment fails, patients can proceed to one of two palliative surgeries, vagus nerve stimulation (VNS) or corpus callosotomy (CC). Their relative seizure control rates in LGS have not been well studied. The purpose of this paper is to compare seizure reduction rates between VNS and CC in LGS using meta-analyses of published data. A systematic search of Pubmed, Ovidsp, and Cochrane was performed to find articles that met the following criteria: (1) prospective or retrospective study, (2) at least one patient diagnosed with Lennox-Gastaut syndrome, and (3) well-defined measure of seizure frequency reduction. Seizure reduction rates were divided into seizure subtypes, as well as total seizures, and categorized as 100%, >75%, and >50%. Patient groups were compared using chi-square tests for categorical variables and t-test for continuous measures. Pooled proportions with 95% confidence interval (95% CI) of seizure outcomes were estimated for total seizures and seizure subtypes using random effects methods. 17 VNS and 9 CC studies met the criteria for inclusion. CC had a significantly better outcome than VNS for >50% atonic seizure reduction (80.0% [67.0-90.0%] vs. 54.1% [32.1-75.4%], p<0.05) and for >75% atonic seizure reduction (70.0% [48.05-87.0%] vs. 26.3% [5.8-54.7%], p<0.05). All other seizure types, as well as total number of seizures, showed no statistically significant difference between VNS and CC. CC may be more beneficial for LGS patients whose predominant disabling seizure type is atonic. For all other seizure types, VNS offers comparable rates to CC. Copyright © 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. Lancman Guido G Department of Neurological Surgery, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. Virk Michael M Shao Huibo H Mazumdar Madhu M Greenfield Jeffrey P JP Weinstein Steven S Schwartz Theodore H TH eng UL1 RR024996 RR NCRR NIH HHS United States UL1 TR000457 TR NCATS NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Meta-Analysis Research Support, N.I.H., Extramural Review 2012 10 12

England Seizure 9306979 1059-1311 Epileptic encephalopathy, Lennox-Gastaut type IM Brain Dev. 2004 Apr;26(3):158-63 15030903 Neurology. 2004 Sep 28;63(6):1124-6 15452317 Neurosurg Focus. 2008 Sep;25(3):E7 18759631 Epilepsy Behav. 2008 Aug;13(2):271-8 18539083 Seizure. 2006 Oct;15(7):552-7 16884930 Childs Nerv Syst. 2006 Aug;22(8):1018-26 16816981 Seizure. 2006 Apr;15(3):198-207 16531077 Seizure. 2005 Oct;14(7):504-13 16176878 Seizure. 2005 Jan;14(1):10-8 15642494 Acta Neurol Scand. 2002 Jan;105(1):13-7 11903103 CMAJ. 2002 Jan 8;166(1):65-6 11800251 Epilepsia. 2001 Sep;42(9):1148-52 11580762 J Child Neurol. 2000 Aug;15(8):509-12 10961788 Drug Saf. 2000 Jun;22(6):467-77 10877040 Neurology. 1999 Nov 10;53(8):1731-5 10563620 Brain Dev. 2008 Mar;30(3):195-9 17825516 Childs Nerv Syst. 2011 May;27(5):787-92 21038079 Paediatr Drugs. 2011 Apr 1;13(2):107-18 21351810 Epilepsy Behav. 2011 Jan;20(1):57-63 21144802 J Neurosurg Pediatr. 2010 Sep;6(3):257-66 20809710 Ital J Pediatr. 2010;36:30 20398284 Epilepsy Res. 1990 Jul;6(2):155-65 2117530 Neurol Med Chir (Tokyo). 1990 Nov;30(12):930-9 1710321 Ann Neurol. 1991 Sep;30(3):357-64 1952824 Epilepsia. 1993;34 Suppl 7:S7-17 8243377 Epilepsia. 1994 May-Jun;35(3):627-36 8026409 Epilepsia. 1994 May-Jun;35(3):637-43 8026410 Epilepsia. 1998 Feb;39(2):201-5 9578001 Epilepsia. 1998 Aug;39(8):809-13 9701369 Pediatrics. 1999 Apr;103(4 Pt 1):778-82 10103302 Neurology. 1999 Apr 12;52(6):1265-7 10214754 Lancet Neurol. 2009 Jan;8(1):82-93 19081517 Seizure. 2009 Mar;18(2):124-8 18799327 J Neurosurg. 2009 Feb;110(2):332-42 19245287 Epilepsia. 2009 May;50(5):1220-8 19170732 Cochrane Database Syst Rev. 2009;(3):CD003277 19588340 Childs Nerv Syst. 2006 Oct;22(10):1322-7 16552568 J Child Neurol. 2009 Aug;24(8 Suppl):24S-32S; quiz 33S-6S 19666880 Epilepsy Behav. 2009 Oct;16(2):321-4 19699154 Corpus Callosum physiology surgery Humans Intellectual Disability therapy Neurosurgery methods Psychosurgery Spasms, Infantile therapy Vagus Nerve Stimulation methods NIHMS462719 PMC3655762 2012 4 9 2012 9 18 2012 9 22 2012 10 12 2012 10 17 6 0 2012 10 17 6 0 2013 7 3 6 0 ppublish S1059-1311(12)00256-7 10.1016/j.seizure.2012.09.014 23068970 PMC3655762 NIHMS462719 23008025 2012 12 24 2013 05 28 2014 01 09

1528-1132 471 1 2013 Jan Clin. Orthop. Relat. Res. Have bilateral total knee arthroplasties become safer? A population-based trend analysis. 17-25 10.1007/s11999-012-2608-9 Studies suggest a trend in the selection of younger and healthier individuals to undergo bilateral TKAs in an attempt to diminish the incidence of complications. It remains unclear whether this development has reduced overall perioperative morbidity and mortality. We investigated whether changes in demographics and comorbidity patterns of patients undergoing bilateral TKAs are detectable and coincide with changes in length and cost of hospitalization, incidence of perioperative complications, morbidity, and mortality. We accessed Nationwide Inpatient Survey data files between 1999 and 2008. One-year periods were created and changes in demographics, length of in-hospital stay, and perioperative morbidity and mortality were analyzed. An estimated 258,524 bilateral TKAs were performed between 1999 and 2008 in the United States. The number of annual procedures increased from 19,288 to 33,679 (75%). Length of hospital stay decreased from 4.98 to 4.01 days. Absolute in-hospital mortality rates decreased at an average rate of 10% per year. The unadjusted percent and adjusted incidence per 1000 inpatient days decreased from 0.42% and 0.85 to 0.16% and 0.39. Although the unadjusted incidence of pneumonia, pulmonary embolism, and nonmyocardial infarction cardiac complications did not change, an increase with time was detectible after adjustment for length of stay. No changes in adjusted incidence were seen for other complications. Although a decreased incidence was seen for some major complications, others either remained unchanged or had an increased incidence when adjusted for length of stay. Future interventions should focus on reducing perioperative risk to improve patient safety. Memtsoudis Stavros G SG Department of Anesthesiology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA. memtsoudiss@hss.edu Mantilla Carlos B CB Parvizi Javad J Stundner Ottokar O Mazumdar Madhu M eng U18 HSO16-75 PHS HHS United States UL1 TR000457 TR NCATS NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. 2012 09 25

United States Clin Orthop Relat Res 0075674 0009-921X AIM IM Anesthesiology. 2002 May;96(5):1140-6 11981154 J Bone Joint Surg Am. 2007 Jun;89(6):1220-6 17545424 J Chronic Dis. 1987;40(5):373-83 3558716 J Clin Epidemiol. 1992 Jun;45(6):613-9 1607900 Med Care. 1994 Jul;32(7):700-15 8028405 Infect Control Hosp Epidemiol. 1997 Apr;18(4):267-74 9131373 Med Care. 1998 Jan;36(1):8-27 9431328 ANZ J Surg. 2005 Sep;75(9):739-46 16173984 Arthritis Rheum. 2005 Dec;52(12):3928-33 16320340 J Bone Joint Surg Am. 2007 Jan;89(1):27-32 17200306 Clin Orthop Relat Res. 2003 Sep;(414):149-56 12966288 Clin Orthop Relat Res. 2008 Nov;466(11):2617-27 18704616 Clin Orthop Relat Res. 2009 Jun;467(6):1568-76 19002540 J Arthroplasty. 2009 Jun;24(4):518-27 18534410 Int Orthop. 2009 Jun;33(3):643-51 18461326 Anesthesiology. 2009 Dec;111(6):1206-16 19934863 Anesth Analg. 2011 Oct;113(4):784-90 21752942 Clin Orthop Relat Res. 2011 Dec;469(12):3462-8 21643923 J Arthroplasty. 2012 Jun;27(6):823-8.e1 22115762 Anesth Analg. 2012 Aug;115(2):321-7 22652311 Clin Orthop Relat Res. 2013 Jan;471(1):13-6 23188652 Age Factors Aged Arthroplasty, Replacement, Knee adverse effects mortality trends Female Hospital Mortality trends Humans Incidence Length of Stay statistics & numerical data trends Male Middle Aged Postoperative Complications epidemiology Prevalence Retrospective Studies Risk Factors Treatment Outcome United States epidemiology PMC3528907 2012 2 13 2012 9 7 2012 9 25 2012 9 26 6 0 2012 9 26 6 0 2013 5 29 6 0 ppublish 10.1007/s11999-012-2608-9 23008025 PMC3528907 22677144 2012 11 13 2013 05 15

1532-8406 27 10 2012 Dec J Arthroplasty The metabolic syndrome in patients undergoing knee and hip arthroplasty: trends and in-hospital outcomes in the United States. 1743-1749.e1 10.1016/j.arth.2012.04.011 S0883-5403(12)00260-4 We evaluated the impact of metabolic syndrome (MetS) on perioperative outcomes in patients undergoing total joint arthroplasty. Using the Nationwide Inpatient Sample, patients with MetS were identified if they had at least 3 of 4 component comorbidities (obesity, dyslipidemia, hypertension, and diabetes). Patient demographics, in-hospital outcomes, and cost were compared between patients with and patients without MetS. Trends were studied for 3-year periods between 2000 and 2008. The prevalence of MetS increased over time, reaching 14% (total knee arthroplasty) and 8.7% (total hip arthroplasty) most recently. Metabolic syndrome was overproportionately prevalent among female total knee arthroplasty recipients, male total hip arthroplasty recipients, and patients in the minority race group. In the regression analysis, MetS was an independent risk factor for the development of major complications, nonroutine discharge, and increased hospital cost. Given the increasing rates of MetS and its association with higher risk for major complications among total joint arthroplasty recipients, further research into the impact of this disease complex is warranted. Copyright © 2012 Elsevier Inc. All rights reserved. Gonzalez Della Valle Alejandro A Department of Orthopedic Surgery, Hospital for Special Surgery, New York, NY, USA. gonzaleza@hss.edu Chiu Ya Lin YL Ma Yan Y Mazumdar Madhu M Memtsoudis Stavros G SG eng Journal Article 2012 06 05

United States J Arthroplasty 8703515 0883-5403 IM Z Orthop Unfall. 2012 Sep;150(4):354 23082337 Arthroplasty, Replacement, Hip economics Arthroplasty, Replacement, Knee economics Female Humans Male Metabolic Syndrome X complications epidemiology Prevalence Treatment Outcome United States epidemiology 2011 8 17 2012 4 11 2012 6 5 2012 6 9 6 0 2012 6 9 6 0 2013 5 17 6 0 ppublish S0883-5403(12)00260-4 10.1016/j.arth.2012.04.011 22677144 22634871 2012 06 21 2013 07 08 2013 11 06

1528-1175 117 1 2012 Jul Anesthesiology Utilization of critical care services among patients undergoing total hip and knee arthroplasty: epidemiology and risk factors. 107-16 10.1097/ALN.0b013e31825afd36 A paucity of data exist on the use of critical care services (CCS) among hip and knee arthroplasty patients. The authors sought to identify the incidence and risk factors for the use of CCS among these patients and compare the characteristics and outcomes of patients who require CCS to those who do not. The authors analyzed hospital discharge data of patients who underwent primary hip or knee arthroplasty in approximately 400 United States hospitals between 2006 and 2010. Patient and healthcare system-related demographics for admitted patients requiring CCS were compared with those who did not. Differences in outcomes, including mortality, complications, disposition status, and hospital charges, were analyzed. Regression analysis was performed to identify risk factors for requiring CCS. A total of 528,495 patients underwent primary total hip (n = 172,467, 33%) and knee arthroplasty (n = 356,028, 67%). Of these, 3% required CCS. On average, CCS patients were older and had a higher comorbidity burden than did patients not requiring CCS. CCS patients experienced more complications, had longer hospital stays and higher costs, and were less likely to be discharged home than were non-CCS patients. Risk factors with increased odds for requiring CCS included advanced age, use of general versus neuraxial anesthesia, and the presence of postoperative cardiopulmonary complications. Approximately 1 of 30 patients undergoing total joint arthroplasty requires CCS. Given the large number of these procedures performed annually, anesthesiologists, orthopedic surgeons, critical care physicians, and administrators should be aware of the attendant risks this population represents and allocate resources accordingly. Memtsoudis Stavros G SG Department of Anesthesiology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA. memtsoudiss@hss.edu Sun Xuming X Chiu Ya-Lin YL Nurok Michael M Stundner Ottokar O Pastores Stephen M SM Mazumdar Madhu M eng AHRQ RFA-HS-05-14 HS AHRQ HHS United States UL1 RR024996 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

United States Anesthesiology 1300217 0003-3022 AIM IM BMJ. 2000 Dec 16;321(7275):1493 11118174 Anesthesiology. 2012 Jan;116(1):229-30; author reply 230 22185885 J Clin Epidemiol. 1992 Jun;45(6):613-9 1607900 Stat Med. 1992 Dec;11(16):2093-109 1293671 Med Care. 1994 Jul;32(7):700-15 8028405 Stat Med. 1998 Oct 15;17(19):2265-81 9802183 Adv Ther. 2006 Jan-Feb;23(1):54-67 16644607 Crit Care Med. 2006 Aug;34(8):2043-8 16763518 J Bone Joint Surg Am. 2007 Apr;89(4):780-5 17403800 J Intensive Care Med. 2007 Mar-Apr;22(2):92-104 17456729 Crit Care Med. 2007 Sep;35(9):2052-6 17568333 Clin Orthop Relat Res. 2008 Nov;466(11):2617-27 18704616 Curr Med Res Opin. 2009 Feb;25(2):385-93 19192983 J Arthroplasty. 2009 Jun;24(4):518-27 18534410 Int Orthop. 2009 Jun;33(3):643-51 18461326 Br J Anaesth. 2009 Sep;103(3):335-45 19628483 Anesthesiology. 2009 Dec;111(6):1206-16 19934863 JAMA. 2010 Jun 23;303(24):2479-85 20571014 Reg Anesth Pain Med. 2010 Sep-Oct;35(5):417-21 20814281 Anesth Analg. 2010 Nov;111(5):1110-6 20841415 Anesthesiology. 2011 Jan;114(1):98-104 21178671 Anesthesiology. 2011 Feb;114(2):283-92 21239971 Anesthesiology. 2011 Jun;114(6):1289-96 21478735 Anesthesiology. 2011 Aug;115(2):315-21 21796055 J Perioper Pract. 2011 Jun;21(6):192-7 21823308 Popul Health Manag. 2011 Oct;14(5):231-8 21506726 J Clin Epidemiol. 2001 Aug;54(8):774-81 11470385 Adult Aged Arthroplasty, Replacement, Hip adverse effects Arthroplasty, Replacement, Knee adverse effects Critical Care utilization Female Humans Length of Stay Male Middle Aged Risk Factors NIHMS462718 PMC3662478 2012 5 29 6 0 2012 5 29 6 0 2013 7 9 6 0 ppublish 10.1097/ALN.0b013e31825afd36 22634871 PMC3662478 NIHMS462718 22434554 2012 08 09 2013 01 07 2013 11 21

1432-1998 42 8 2012 Aug Pediatr Radiol Visualization of the normal appendix with MR enterography in children. 959-64 10.1007/s00247-012-2377-3 Magnetic resonance (MR) imaging may provide a radiation-sparing alternative to CT in diagnosing appendicitis in children in whom US is equivocal. However, comparability with CT in the detection of the appendix remains to be established. To determine the detection rate of the normal appendix in children on oral and IV contrast-enhanced MRI. MR imaging of 58 patients who had previously undergone MR enterography was retrospectively reviewed. Detection rate, body mass index, age and gender were recorded. The normal appendix was detected in 28 cases (48%), with greatest detection rate on the axial fast imaging employing steady-state acquisition (FIESTA) sequence. Children in whom the appendix was detected had significantly higher BMI compared to children in whom the appendix was not seen. Neither age nor gender demonstrated a significant association with detection rate. The detection rate of the normal appendix in children on oral and IV contrast-enhanced MRI was 48%, which is comparable to detection rates on CT, as well as to previously reported detection rates on MR imaging with neither oral nor IV contrast agents. These findings may serve to guide the development of MRI protocols for pediatric appendicitis. Kovanlikaya Arzu A Department of Radiology, Weill Cornell Medical College, New York Presbyterian Hospital, 525 E 68th St, Rm F631E, New York, NY 10065, USA. ark2011@med.cornell.edu Rosenbaum Daniel D Mazumdar Madhu M Dunning Allison A Brill Paula W PW eng Journal Article 2012 03 21

Germany Pediatr Radiol 0365332 0301-0449 0 Contrast Media K2I13DR72L Gadolinium DTPA IM Adolescent Appendix anatomy & histology Child Contrast Media administration & dosage Female Gadolinium DTPA administration & dosage Humans Magnetic Resonance Imaging methods Male Reference Values Retrospective Studies Young Adult 2012 1 25 2012 2 1 2012 2 1 2012 3 21 2012 3 22 6 0 2012 3 22 6 0 2013 1 8 6 0 ppublish 10.1007/s00247-012-2377-3 22434554 22426260 2012 03 19 2012 05 04 2013 11 21

1530-0358 55 4 2012 Apr Dis. Colon Rectum FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. 378-86 10.1097/DCR.0b013e318244a666 At present there is no defined role for routine FDG-PET in the preoperative evaluation of nonmetastatic rectal cancer. The primary objective of this study was to evaluate the ability of FDG-PET to predict long-term prognosis based on the response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. This was a prospective study. This study was performed at an academic, tertiary care, comprehensive cancer center. One hundred twenty-seven patients with locally advanced rectal cancer were enrolled between September 1999 and December 2005. All patients underwent FDG-PET scans before and after neoadjuvant chemoradiotherapy. FDG-PET parameters were evaluated by at least 2 study board-certified nuclear medicine physicians, and included mean standard uptake value, maximum standard uptake value, total lesion glycolysis, and visual response score. The main outcome measures were time to recurrence and disease-specific survival. Of 127 patients, 82 (65%) were men, the median age was 60 years (range, 27-82), 110 patients had stage II/III disease, and 17 patients had stage IV disease. Median follow-up among survivors was 77 months (range, 1-115 months). Nine patients had unresectable metastatic disease and were excluded from the time-to-recurrence analysis. At 5 years, 74% (95% CI = 66%-81%) of patients had not had recurrences (locally and/or distantly). The 5-year disease-specific survival was 89% (95% CI = 81%-93%). On univariate analysis, visual response score and time to recurrence came closest to having an association (HR = 0.83, 95% CI = 0.68-1.01, p = 0.06). On multivariate analysis, the visual response score was not significant (p = 0.85). No FDG-PET parameter was associated with disease-specific survival. Assessment of rectal cancer response to neoadjuvant chemoradiotherapy by FDG-PET provides no prognostic information. Therefore, serial FDG-PET before and after neoadjuvant chemoradiotherapy should not be performed for this purpose. Ruby Jeannine A JA Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Leibold Tobias T Akhurst Timothy J TJ Shia Jinru J Saltz Leonard B LB Mazumdar Madhu M Riedel Elyn R ER Larson Steven M SM Guillem José G JG eng R01 CA 82534 CA NCI NIH HHS United States Journal Article Research Support, N.I.H., Extramural

United States Dis Colon Rectum 0372764 0012-3706 0 Radiopharmaceuticals 0Z5B2CJX4D Fluorodeoxyglucose F18 IM Adult Aged Aged, 80 and over Chemoradiotherapy methods Female Fluorodeoxyglucose F18 diagnostic use Humans Male Middle Aged Neoadjuvant Therapy Neoplasm Staging Positron-Emission Tomography Predictive Value of Tests Prognosis Proportional Hazards Models Prospective Studies Radiopharmaceuticals diagnostic use Rectal Neoplasms pathology radionuclide imaging therapy Survival Rate Treatment Outcome 2012 3 20 6 0 2012 3 20 6 0 2012 5 5 6 0 ppublish 10.1097/DCR.0b013e318244a666 00003453-201204000-00003 22426260 22305625 2012 03 14 2012 07 25 2013 10 14

1873-4529 24 2 2012 Mar J Clin Anesth Factors influencing unexpected disposition after orthopedic ambulatory surgery. 89-95 10.1016/j.jclinane.2011.10.002 To analyze whether patient characteristics, ambulatory facility type, anesthesia provider and technique, procedure type, and temporal factors impact the outcome of unexpected disposition after ambulatory knee and shoulder surgery. Retrospective analysis of a national database. Freestanding and hospital-based ambulatory surgery facilities. Ambulatory knee and shoulder surgery cases from 1996 and 2006 were identified through the National Survey of Ambulatory Surgery. The incidence of unexpected disposition status was determined and risk factors for such outcome were analyzed. Factors independently increasing the risk for unexpected disposition included procedures performed in hospital-based versus freestanding facilities [odds ratio (OR) 6.83 (95% confidence interval [CI] 4.34; 10.75)], shoulder versus knee procedures [OR 3.84 (CI 2.55; 5.77)], anesthesia provided by nonanesthesiology professionals and certified registered nurse-anesthetists versus anesthesiologists [OR 7.33 (CI 4.18; 12.84) and OR 1.80 (CI 1.09; 2.99), respectively]. Decreased risk for unexpected disposition was for procedures performed in 2006 versus 1996 [OR 0.15 (CI 0.10; 0.24)] and the use of anesthesia other than regional or general [OR 0.34 (CI 0.18; 0.68)]. The decreased risk for unexpected disposition associated with more recent data and with freestanding versus hospital-based facilities may represent improvements in efficiency, while the decreased odds for such disposition status associated with the use of other than general or regional anesthesia may be related to a lower invasiveness of cases. We found an increased risk of adverse disposition in cases where the anesthesia provider was a nonanesthesiology professional. No difference in this outcome was noted when an anesthesia care team provided care. Copyright © 2012 Elsevier Inc. All rights reserved. Memtsoudis Stavros G SG Department of Anesthesiology, Hospital for Special Surgery, New York, NY 10021, USA. MemtsoudisS@hss.edu Ma Yan Y Swamidoss Cephas P CP Edwards Alison M AM Mazumdar Madhu M Liguori Gregory A GA eng UL1 RR024996 RR NCRR NIH HHS United States UL1 RR024996-05 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. 2012 02 04

United States J Clin Anesth 8812166 0952-8180 IM Adv Data. 1997 Dec 24;(296):1-15 10182647 Vital Health Stat 1. 1997 Oct;(37):I-IV, 1-124 9478250 Spine (Phila Pa 1976). 2006 Aug 1;31(17):1957-63; discussion 1964 16924213 Arch Surg. 2007 Mar;142(3):263-8 17372051 Int Braz J Urol. 2007 May-Jun;33(3):330-8 17626649 Natl Health Stat Report. 2009 Jan 28;(11):1-25 19294964 Anesth Analg. 2010 Oct;111(4):1011-5 20802051 Reg Anesth Pain Med. 2011 Jul-Aug;36(4):327-31 21490521 J Clin Anesth. 2006 Aug;18(5):328-33 16905076 Anesth Analg. 2000 Oct;91(4):860-4 11004038 Anesthesiology. 2002 Apr;96(4):994-1003 11964610 Anesthesiol Clin North America. 2003 Jun;21(2):289-303 12812396 Health Aff (Millwood). 1989 Spring;8(1):158-70 2651259 Stat Methods Med Res. 1996 Sep;5(3):239-61 8931195 J Clin Anesth. 2012 Mar;24(2):87-8 22301209 Adolescent Adult Aged Ambulatory Care Facilities statistics & numerical data Ambulatory Surgical Procedures methods statistics & numerical data Anesthesia methods Anesthesiology methods statistics & numerical data Databases, Factual Female Humans Knee Joint surgery Male Middle Aged Orthopedic Procedures methods statistics & numerical data Outcome Assessment (Health Care) Patient Discharge statistics & numerical data Retrospective Studies Risk Factors Shoulder Joint surgery United States Young Adult NIHMS347862 PMC3303976 2011 6 17 2011 9 13 2011 10 12 2012 2 4 2012 2 7 6 0 2012 2 7 6 0 2012 7 26 6 0 ppublish S0952-8180(12)00002-5 10.1016/j.jclinane.2011.10.002 22305625 PMC3303976 NIHMS347862 22235286 2012 01 11 2012 05 14 2013 10 15

1932-6203 7 1 2012 PLoS ONE Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. e29336 10.1371/journal.pone.0029336 The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends, at least in part, on the assumption that metastatic tumors are primarily clonal with respect to mutant oncogene. With the emergence of BRAF(V600E) as a therapeutic target, we investigated intra- and inter-tumor heterogeneity in melanoma using detection of the BRAF(V600E) mutation as a marker of clonality. BRAF mutant-specific PCR (MS-PCR) and conventional sequencing were performed on 112 tumors from 73 patients, including patients with matched primary and metastatic specimens (n = 18). Nineteen patients had tissues available from multiple metastatic sites. Mutations were detected in 36/112 (32%) melanomas using conventional sequencing, and 85/112 (76%) using MS-PCR. The better sensitivity of the MS-PCR to detect the mutant BRAF(V600E) allele was not due to the presence of contaminating normal tissue, suggesting that the tumor was comprised of subclones of differing BRAF genotypes. To determine if tumor subclones were present in individual primary melanomas, we performed laser microdissection and mutation detection via sequencing and BRAF(V600E)-specific SNaPshot analysis in 9 cases. Six of these cases demonstrated differing proportions of BRAF(V600E)and BRAF(wild-type) cells in distinct microdissected regions within individual tumors. Additional analyses of multiple metastatic samples from individual patients using the highly sensitive MS-PCR without microdissection revealed that 5/19 (26%) patients had metastases that were discordant for the BRAF(V600E) mutation. In conclusion, we used highly sensitive BRAF mutation detection methods and observed substantial evidence for heterogeneity of the BRAF(V600E) mutation within individual melanoma tumor specimens, and among multiple specimens from individual patients. Given the varied clinical responses of patients to BRAF inhibitor therapy, these data suggest that additional studies to determine possible associations between clinical outcomes and intra- and inter-tumor heterogeneity could prove fruitful. Yancovitz Molly M Department of Dermatology, New York University Langone Medical Center, New York, New York, United States of America. Litterman Adam A Yoon Joanne J Ng Elise E Shapiro Richard L RL Berman Russell S RS Pavlick Anna C AC Darvishian Farbod F Christos Paul P Mazumdar Madhu M Osman Iman I Polsky David D eng 5P30CA16087-31 CA NCI NIH HHS United States R21 CA109388 CA NCI NIH HHS United States T32 AR07190 - 31 AR NIAMS NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. 2012 01 03

United States PLoS One 101285081 1932-6203 EC 2.7.11.1 BRAF protein, human EC 2.7.11.1 Proto-Oncogene Proteins B-raf IM Br J Cancer. 2010 Jun 8;102(12):1724-30 20531415 Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200 20149136 N Engl J Med. 2010 Aug 26;363(9):809-19 20818844 Pigment Cell Melanoma Res. 2010 Dec;23(6):760-2 20973931 Nature. 2010 Dec 16;468(7326):968-72 21107320 Nature. 2010 Dec 16;468(7326):973-7 21107323 J Mol Diagn. 2011 Jan;13(1):74-84 21227397 Oncogene. 2011 Jan 20;30(3):366-71 20818433 Br J Cancer. 2011 Feb 1;104(3):464-8 21224857 Nature. 2011 Apr 7;472(7341):90-4 21399628 N Engl J Med. 2011 Jun 30;364(26):2507-16 21639808 Mod Pathol. 2011 Jul;24(7):974-82 21423156 Nature. 2002 Jun 27;417(6892):949-54 12068308 Nat Genet. 2003 Jan;33(1):19-20 12447372 Cancer Res. 2003 Jul 15;63(14):3883-5 12873977 Cancer Res. 2003 Jul 15;63(14):3955-7 12873990 Clin Cancer Res. 2003 Aug 15;9(9):3362-8 12960123 Am J Dermatopathol. 2003 Oct;25(5):365-70 14501284 Cancer Res. 2003 Sep 1;63(17):5198-202 14500344 J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90 14679157 Clin Cancer Res. 2004 Mar 1;10(5):1753-7 15014028 Oncogene. 2004 Aug 12;23(36):6031-9 15208655 J Invest Dermatol. 2004 Nov;123(5):990-2 15482489 Science. 1977 Aug 26;197(4306):893-5 887927 Nat Genet. 2006 Apr;38(4):468-73 16565718 Oncogene. 2006 Jun 8;25(24):3357-64 16462768 J Mol Diagn. 2007 Apr;9(2):178-83 17384209 Cancer Res. 2007 Jun 15;67(12):5814-20 17575149 Am J Surg Pathol. 2007 Jul;31(7):1029-37 17592269 Curr Opin Oncol. 2008 Mar;20(2):183-9 18300768 Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38 18353141 Cancer Sci. 2008 May;99(5):929-35 18325048 J Pathol. 2008 Sep;216(1):64-74 18623623 Clin Cancer Res. 2008 Dec 15;14(24):8302-7 19088048 J Natl Cancer Inst. 2009 Oct 21;101(20):1423-7 19752400 Br J Cancer. 2009 Nov 17;101(10):1724-30 19861964 Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6 19915144 Cell. 2010 Jan 22;140(2):209-21 20141835 Nature. 2010 Mar 18;464(7287):431-5 20130576 Nature. 2010 Mar 18;464(7287):427-30 20179705 Oncogene. 2010 Sep 2;29(35):4905-13 20581869 Base Sequence DNA Mutational Analysis Humans Melanoma genetics pathology secondary Microdissection Mutation Neoplasm Metastasis Polymerase Chain Reaction Proto-Oncogene Proteins B-raf genetics PMC3250426 2011 8 1 2011 11 25 2012 1 3 2012 1 12 6 0 2012 1 12 6 0 2012 5 15 6 0 ppublish 10.1371/journal.pone.0029336 PONE-D-11-14676 22235286 PMC3250426 22189576 2011 12 22 2012 07 30 2013 10 15

1532-8651 37 1 2012 Jan-Feb Reg Anesth Pain Med Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. 99-105 10.1097/AAP.0b013e31823ebc74 Research in the field of anesthesiology relies heavily on longitudinal designs for answering questions about long-term efficacy and safety of various anesthetic and pain regimens. Yet, anesthesiology research is lagging in the use of advanced statistical methods for analyzing longitudinal data. The goal of this article was to increase awareness of the advantages of modern statistical methods and promote their use in anesthesia research. Here we introduce 2 modern and advanced statistical methods for analyzing longitudinal data: the generalized estimating equations (GEE) and mixed-effects models (MEM). These methods were compared with the conventional repeated-measures analysis of variance (RM-ANOVA) through a clinical example with 2 types of end points (continuous and binary). In addition, we compared GEE and MEM to RM-ANOVA through a simulation study with varying sample sizes, varying number of repeated measures, and scenarios with and without missing data. In the clinical study, the 3 methods are found to be similar in terms of statistical estimation, whereas the parameter interpretations are somewhat different. The simulation study shows that the methods of GEE and MEM are more efficient in that they are able to achieve higher power with smaller sample size or lower number of repeated measurements in both complete and missing data scenarios. Based on their advantages over RM-ANOVA, GEE and MEM should be strongly considered for the analysis of longitudinal data. In particular, GEE should be used to explore overall average effects, and MEM should be used when subject-specific effects (in addition to overall average effects) are of primary interest. Ma Yan Y Research Division, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA. may@hss.edu Mazumdar Madhu M Memtsoudis Stavros G SG eng RFA-HS-05-14 HS AHRQ HHS United States UL1 RR024996 RR NCRR NIH HHS United States UL1 RR024996-01 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

United States Reg Anesth Pain Med 9804508 1098-7339 IM Reg Anesth Pain Med. 2010 Nov-Dec;35(6):529-34 20975468 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):535-8 20975469 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):539-43 20975470 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):559-64 20975475 Biometrics. 1986 Mar;42(1):121-30 3719049 Am J Epidemiol. 1987 Aug;126(2):310-8 3300281 Ann N Y Acad Sci. 1963 May 22;107:539-56 14025561 J Biopharm Stat. 2009 Nov;19(6):1055-73 20183464 Reg Anesth Pain Med. 2010 Sep-Oct;35(5):409-11 20814280 Reg Anesth Pain Med. 2010 Sep-Oct;35(5):417-21 20814281 Reg Anesth Pain Med. 2010 Sep-Oct;35(5):422-6 20814282 Reg Anesth Pain Med. 2010 Sep-Oct;35(5):427-31 20814283 Reg Anesth Pain Med. 2010 Sep-Oct;35(5):412-6 20830870 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):490-5 20975461 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):500-6 20975463 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):507-13 20975464 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):520-4 20975466 Reg Anesth Pain Med. 2010 Nov-Dec;35(6):525-8 20975467 Analysis of Variance Anesthesiology statistics & numerical data Arthroplasty, Replacement, Knee adverse effects Biomedical Research statistics & numerical data Computer Simulation Data Interpretation, Statistical Humans Longitudinal Studies Models, Statistical Pain, Postoperative diagnosis etiology prevention & control Randomized Controlled Trials as Topic Research Design statistics & numerical data Time Factors Tourniquets Treatment Outcome NIHMS340655 PMC3249227 2011 12 23 6 0 2011 12 23 6 0 2012 7 31 6 0 ppublish 10.1097/AAP.0b013e31823ebc74 00115550-201201000-00016 22189576 PMC3249227 NIHMS340655 22115762 2012 05 21 2013 01 02 2013 10 16

1532-8406 27 6 2012 Jun J Arthroplasty In-hospital patient falls after total joint arthroplasty: incidence, demographics, and risk factors in the United States. 823-8.e1 10.1016/j.arth.2011.10.010 In-hospital falls (IFs) increase morbidity, cost, and may result in litigation. We analyzed the Nationwide Inpatient Sample to quantify the incidence of IFs in patients who underwent hip and knee arthroplasty and to define trends, patient's demographics, risk factors, complications, and hospital cost. Patients operated on between 1998 and 2007 were identified and grouped depending on the presence of a diagnosis of IF. Of those, 0.85% had an IF, representing 2.1 falls per 1000 inpatient days. The incidence of IF increased from 0.4% to 1.3% during the study period. Independent risk factors included revision surgery, advanced age, male sex, minority race, and the presence of comorbidities. Patients having IF had a longer hospital stay and were less likely to be discharged to their primary residence. In-hospital mortality, complications, and cost were higher in patients sustaining IF. Given the associated morbidity, mortality, and increased cost, resources should be allocated to minimize the risk of IF in this population. Copyright © 2012 Elsevier Inc. All rights reserved. Memtsoudis Stavros G SG Department of Anesthesiology, Hospital for Special Surgery, New York, New York 10021, USA. Dy Christopher J CJ Ma Yan Y Chiu Ya-Lin YL Della Valle Alejandro Gonzalez AG Mazumdar Madhu M eng UL1 RR024996 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2011 11 23

United States J Arthroplasty 8703515 0883-5403 IM Infect Control Hosp Epidemiol. 1990 Oct;11(10):521-4 2230041 Arch Phys Med Rehabil. 1990 Jan;71(1):8-12 2297314 Scand J Caring Sci. 1992;6(2):113-8 1641531 Stat Med. 1992 Dec;11(16):2093-109 1293671 Aust Clin Rev. 1993;13(3):141-9 8250776 Adv Data. 1995 Jul 6;(265):1-12 10154340 Scand J Soc Med. 1997 Mar;25(1):8-13 9106939 Nurs Manage. 1998 Mar;29(3):24-6 9544027 Clin Geriatr Med. 1998 Nov;14(4):699-726 9799475 J Gerontol Nurs. 1998 Dec;24(12):7-15 10025306 Pflege. 1998 Dec;11(6):335-41 10427278 Infect Control Hosp Epidemiol. 2005 Oct;26(10):822-7 16276957 J Bone Joint Surg Am. 2007 Oct;89 Suppl 3:144-51 17908880 Clin Orthop Relat Res. 2008 Apr;466(4):914-9 18213506 J Arthroplasty. 2009 Jun;24(4):518-27 18534410 Int Orthop. 2009 Jun;33(3):643-51 18461326 Anesthesiology. 2009 Dec;111(6):1206-16 19934863 J Arthroplasty. 2010 Jan;25(1):10-4 19062249 J Arthroplasty. 2010 Sep;25(6 Suppl):58-61 20570479 Am J Orthop (Belle Mead NJ). 2010 Aug;39(8):E72-7 20882208 Anesth Analg. 2010 Nov;111(5):1110-6 20841415 Am J Orthop (Belle Mead NJ). 2010 Sep;39(9):E95-102 21290031 J Nurs Care Qual. 2000 Apr;14(3):43-53 10826234 Z Gerontol Geriatr. 2004 Feb;37(1):9-14 14991290 J Gen Intern Med. 2004 Jul;19(7):732-9 15209586 Geriatrics. 1977 Apr;32(4):101-8 844693 Gerontologist. 1983 Jun;23(3):273-6 6873696 J Chronic Dis. 1987;40(5):373-83 3558716 QRB Qual Rev Bull. 1988 Dec;14(12):369-71 3146043 Kans Nurse. 1989 Oct;64(10):3-5 2585952 J Clin Epidemiol. 1992 Jun;45(6):613-9 1607900 Accidental Falls economics statistics & numerical data Adult Age Factors Aged Aged, 80 and over Arthroplasty, Replacement, Hip economics statistics & numerical data Arthroplasty, Replacement, Knee economics statistics & numerical data Comorbidity Female Hospital Costs Humans Incidence Inpatients statistics & numerical data Male Middle Aged Reoperation economics statistics & numerical data Retrospective Studies Risk Factors Sex Factors United States epidemiology NIHMS464226 PMC3653584 2011 2 15 2011 10 7 2011 11 23 2011 11 26 6 0 2011 11 26 6 0 2013 1 3 6 0 ppublish S0883-5403(11)00558-4 10.1016/j.arth.2011.10.010 22115762 PMC3653584 NIHMS464226 22024892 2012 05 11 2012 09 07 2013 10 16

1528-1159 37 11 2012 May 15 Spine Metabolic syndrome and lumbar spine fusion surgery: epidemiology and perioperative outcomes. 989-95 10.1097/BRS.0b013e31823a3a13 Analysis of the National Inpatient Sample database from 2000 to 2008. To identify whether metabolic syndrome is an independent risk factor for increased major perioperative complications, cost, length of stay, and nonroutine discharge. Metabolic syndrome is a combination of medical disorders that has been shown to increase the health risk of the general population. No study has analyzed its impact in the perioperative spine surgery setting. We obtained the National Inpatient Sample from the Hospital Cost and Utilization Project for each year between 2000 and 2008. All patients undergoing primary posterior lumbar spine fusion were identified and separated into groups with and without metabolic syndrome. Patient demographics and health care system-related parameters were compared. The outcomes of major complications, nonroutine discharge, length of hospital stay, and hospitalization charges were assessed for both groups. Regression analysis was performed to identify whether the presence of metabolic syndrome was an independent risk factor for each outcome. An estimated 1,152,747 primary posterior lumbar spine fusions were performed between 2000 and 2008 in the United States. The prevalence of metabolic syndrome as well as the comorbidities of the patients increased significantly over time. Patients with metabolic syndrome had significantly longer length of stay, higher hospital charges, higher rates of nonroutine discharges, and increased rates of major life-threatening complications than patients without metabolic syndrome. Patients with metabolic syndrome undergoing primary posterior lumbar spinal fusion represent an increasing financial burden on the health care system. Clinicians should recognize that metabolic syndrome represents a risk factor for increased perioperative morbidity. Memtsoudis Stavros G SG Department of Anesthesiology, Hospital for Special Surgery, New York, NY 10021, USA. MemtsoudisS@hss.edu Kirksey Meghan M Ma Yan Y Chiu Ya Lin YL Mazumdar Madhu M Pumberger Matthias M Girardi Federico P FP eng RFA-HS-05-14 HS AHRQ HHS United States UL1 RR024996 RR NCRR NIH HHS United States UL1 RR024996-05 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

United States Spine (Phila Pa 1976) 7610646 0362-2436 IM Diabetes Care. 2011 Jan;34(1):216-9 20889854 J Diabetes. 2010 Sep;2(3):180-93 20923483 JAMA. 2001 May 16;285(19):2486-97 11368702 JAMA. 2002 Dec 4;288(21):2709-16 12460094 Circulation. 2004 Jan 27;109(3):433-8 14744958 Obes Surg. 2004 Sep;14(8):1042-50 15487110 J Chronic Dis. 1987;40(5):373-83 3558716 J Clin Epidemiol. 1992 Jun;45(6):613-9 1607900 Med Care. 1994 Jul;32(7):700-15 8028405 Adv Data. 1995 Jul 6;(265):1-12 10154340 Lancet. 2005 Sep 24-30;366(9491):1059-62 16182882 Spine (Phila Pa 1976). 2006 Aug 1;31(17):1957-63; discussion 1964 16924213 Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):482-9 16932765 Curr Cardiol Rep. 2006 Nov;8(6):433-8 17059795 Natl Health Stat Report. 2009 May 5;(13):1-7 19634296 Am J Crit Care. 2009 Sep;18(5):468-73 19723867 Anesthesiology. 2009 Dec;111(6):1206-16 19934863 Am J Cardiol. 2010 May 1;105(9):1306-12 20403484 J Rheumatol. 2010 Sep;37(9):1917-22 20634242 Anesthesiology. 2010 Oct;113(4):859-72 20808207 Diabetes Care. 2001 Apr;24(4):683-9 11315831 Adult Aged Comorbidity Cost of Illness Female Hospital Charges statistics & numerical data Hospital Costs statistics & numerical data Humans Length of Stay economics statistics & numerical data Lumbar Vertebrae surgery Male Metabolic Syndrome X complications epidemiology Outcome Assessment (Health Care) economics Postoperative Complications economics etiology Prevalence Regression Analysis Risk Assessment Risk Factors Spinal Fusion economics methods statistics & numerical data United States epidemiology NIHMS335383 PMC3288758 2011 10 26 6 0 2011 10 26 6 0 2012 9 8 6 0 ppublish 10.1097/BRS.0b013e31823a3a13 22024892 PMC3288758 NIHMS335383 22020835 2012 06 07 2012 08 15 2013 10 16

1097-0142 118 12 2012 Jun 15 Cancer Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment. 3145-52 10.1002/cncr.26619 Prostate cancer (PCa) racial disparity studies typically focus on survival differences after curative treatment. The authors of this report hypothesized that comparing mortality rates between African American (AA) and Caucasian American (CA) patients who deferred primary treatment for clinically nonmetastatic PCa may provide a better assessment of the impact of race on the natural course of PCa. The pathology database of the New York Veterans Administration Medical Center (VAMC), an equal access-of-care facility, was searched for patients with biopsy-proven PCa. Inclusion criteria included 1) no evidence of metastatic disease or death within 3 years after diagnosis, 2) no primary treatment, and 3) a minimum of 5 years of follow-up for survivors. In total, 518 patients met inclusion criteria between 1990 and 2005. AA patients were younger (P = .02) and had higher median prostate-specific antigen (PSA) levels (P = .001) at the time of diagnosis compared with CA patients. In a multivariate model, higher Gleason score and PSA level were associated with increased mortality (P = .001 and P = .03, respectively), but race was not a predictor of death from PCa. The current data suggested that race did not have a major impact on survival in patients with PCa who deferred primary treatment for clinically nonmetastatic disease. Copyright © 2011 American Cancer Society. Koscuiszka Michael M Department of Urology, New York University School of Medicine, New York, New York 10016, USA. Hatcher David D Christos Paul J PJ Rose Amy E AE Greenwald Holly S HS Chiu Ya-lin YL Taneja Samir S SS Mazumdar Madhu M Lee Peng P Osman Iman I eng 1U01CA149556-01 CA NCI NIH HHS United States 1UL1RR029893 RR NCRR NIH HHS United States PC080010 PC NCI NIH HHS United States U01 CA149556 CA NCI NIH HHS United States UL1 RR024996 RR NCRR NIH HHS United States UL1 RR029893 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2011 10 21

United States Cancer 0374236 0008-543X EC 3.4.21.77 Prostate-Specific Antigen AIM IM Med Care. 2009 Feb;47(2):176-83 19169118 BJU Int. 2009 Jan;103(1):38-42 18778352 N Engl J Med. 2009 Mar 26;360(13):1320-8 19297566 Cancer. 2009 Jul 1;115(13 Suppl):3100-6 19544551 J Natl Cancer Inst. 2001 Mar 7;93(5):388-95 11238701 Urology. 2002 Oct;60(4):670-4 12385931 J Urol. 2002 Dec;168(6):2510-5 12441951 J Urol. 2003 Nov;170(5):1804-7 14532780 Urol Oncol. 2004 Jan-Feb;22(1):20-4 14969799 J Gen Intern Med. 2004 Feb;19(2):146-55 15009794 J Urol. 2004 Apr;171(4):1508-12 15017209 Brachytherapy. 2003;2(2):77-84 15062144 JAMA. 1994 Feb 2;271(5):368-74 7506797 J Clin Oncol. 2004 Dec 1;22(23):4725-9 15570072 Med Care Res Rev. 2009 Aug;66(4):409-35 19357389 Eur Urol. 2009 Jun;55(6):1321-30 19286302 Urol Oncol. 2009 Nov-Dec;27(6):668-72 19879477 J Clin Oncol. 2010 Jan 1;28(1):126-31 19917860 BJU Int. 2011 Feb;107(4):576-84 20735387 Eur J Cancer. 2011 Mar;47(4):545-53 21087857 J Clin Oncol. 2011 Jun 1;29(16):2185-90 21464416 Prostate Cancer Prostatic Dis. 2011 Sep;14(3):262-5 21519348 BJU Int. 2005 May;95(7):956-60 15839912 Cancer. 2005 May 1;103(9):1819-25 15795905 BJU Int. 2005 Jul;96(1):29-33 15963115 Urology. 2006 Jan;67(1):120-4 16413346 Cancer. 2006 Mar 15;106(6):1276-85 16475208 J Urol. 2006 Aug;176(2):439-49 16813862 Urology. 2006 Jul;68(1):89-93 16844451 Br J Cancer. 2006 Nov 6;95(9):1186-94 17077805 Biostatistics. 2007 Apr;8(2):184-96 16636138 J Urol. 2007 Dec;178(6):2359-64; discussion 2364-5 17936806 Cancer. 2008 Jan 1;112(1):69-74 18000803 Eur Urol. 2008 Feb;53(2):347-54 17544572 BJU Int. 2008 Jan;101(2):165-9 17850361 Eur Urol. 2008 Mar;53(3):457-60 18079050 BJU Int. 2008 Mar;101 Suppl 2:16-22 18307688 Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):636-44 18349281 Cancer. 2008 Jun 15;112(12):2664-70 18433013 Urology. 2008 Sep;72(3):641-6 18295314 J Urol. 2008 Oct;180(4):1336-9; discussion 1340-1 18707696 J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5 18707731 Eur Urol. 2008 Dec;54(6):1297-305 18342430 N Engl J Med. 2009 Mar 26;360(13):1310-9 19297565 African Continental Ancestry Group Age Factors Aged Biopsy Disease-Free Survival European Continental Ancestry Group Humans Male Palliative Care Prostate-Specific Antigen Prostatic Neoplasms ethnology mortality pathology therapy Risk Factors Watchful Waiting methods NIHMS452417 PMC3623265 2011 6 27 2011 8 26 2011 9 19 2011 10 21 2011 10 25 6 0 2011 10 25 6 0 2012 8 16 6 0 ppublish 10.1002/cncr.26619 22020835 PMC3623265 NIHMS452417 21851550 2012 02 20 2012 04 23

1464-410X 109 5 2012 Mar BJU Int. Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. 685-90 10.1111/j.1464-410X.2011.010419.x • To employ decision curve analysis to determine the impact of nuclear matrix protein 22 (NMP22) on clinical decision making in the detection of bladder cancer using data from a prospective trial. • The study included 1303 patients at risk for bladder cancer who underwent cystoscopy, urine cytology and measurement of urinary NMP22 levels. • We constructed several prediction models to estimate risk of bladder cancer. The base model was generated using patient characteristics (age, gender, race, smoking and haematuria); cytology and NMP22 were added to the base model to determine effects on predictive accuracy. • Clinical net benefit was calculated by summing the benefits and subtracting the harms and weighting these by the threshold probability at which a patient or clinician would opt for cystoscopy. • In all, 72 patients were found to have bladder cancer (5.5%). In univariate analyses, NMP22 was the strongest predictor of bladder cancer presence (predictive accuracy 71.3%), followed by age (67.5%) and cytology (64.3%). • In multivariable prediction models, NMP22 improved the predictive accuracy of the base model by 8.2% (area under the curve 70.2-78.4%) and of the base model plus cytology by 4.2% (area under the curve 75.9-80.1%). • Decision curve analysis revealed that adding NMP22 to other models increased clinical benefit, particularly at higher threshold probabilities. • NMP22 is a strong, independent predictor of bladder cancer. • Addition of NMP22 improves the accuracy of standard predictors by a statistically and clinically significant margin. • Decision curve analysis suggests that integration of NMP22 into clinical decision making helps avoid unnecessary cystoscopies, with minimal increased risk of missing a cancer. © 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. Barbieri Christopher E CE Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY 10065, USA. Cha Eugene K EK Chromecki Thomas F TF Dunning Allison A Lotan Yair Y Svatek Robert S RS Scherr Douglas S DS Karakiewicz Pierre I PI Sun Maxine M Mazumdar Madhu M Shariat Shahrokh F SF eng UL1-RR02499 RR NCRR NIH HHS United States Journal Article Multicenter Study Research Support, N.I.H., Extramural 2011 08 18

England BJU Int 100886721 1464-4096 0 Nuclear Proteins 0 nuclear matrix protein 22 IM Aged Carcinoma, Transitional Cell diagnosis urine Clinical Trials as Topic Decision Support Techniques Female Humans Male Middle Aged Nuclear Proteins urine Prospective Studies Retrospective Studies Urinary Bladder Neoplasms diagnosis urine 2011 8 18 2011 8 20 6 0 2011 8 20 6 0 2012 4 24 6 0 ppublish 10.1111/j.1464-410X.2011.010419.x 21851550 21778465 2012 09 04 2013 01 17 2014 03 28

1525-1489 27 5 2012 Sep-Oct J Intensive Care Med Mortality of patients with respiratory insufficiency and adult respiratory distress syndrome after surgery: the obesity paradox. 306-11 10.1177/0885066611411410 Obesity has long been considered a risk factor for the development of various pathologies, yet evidence supporting increased risk of perioperative mortality in obese individuals developing postoperative complications is limited. Therefore, we sought to characterize the demographics of obese and nonobese individuals developing postoperative respiratory insufficiency (RI)/adult respiratory distress syndrome (ARDS) and to quantify the impact of obesity on in-hospital mortality among this patient population utilizing data collected for the Nationwide Inpatient Sample (NIS). Nationwide Inpatient Sample data for each year between 1998 and 2007 were accessed. Entries were included if they underwent a surgical procedure and had a diagnosis of RI/ARDS following surgery. Patients fulfilling entry criteria were divided into those with and without obesity. In-hospital mortality was the primary outcome. A logistic regression model was fitted to elucidate if obesity was associated with increased odds for the outcome while controlling for age, gender, admission and procedure type, and comorbidity burden. We identified 9 149 030 admissions that underwent the included surgical procedures between 1998 and 2007. Of those, 5.48% had a diagnosis of obesity. The incidence of RI/ARDS was 1.82% among obese and 2.01% among nonobese patients. Obese patients whose postoperative course was complicated by RI/ARDS had a significantly lower incidence of the need for mechanical ventilation (50% vs 55%). In-hospital mortality was significantly lower compared to nonobese patients (5.45% vs 18.72%). For those patients with RI/ARDS requiring intubation, the in-hospital mortality rate was 11% for obese and 25% for nonobese patients. In the multivariate regression analysis, obesity was associated with a 69% reduction in the odds of in-hospital mortality in postoperative patients with RI/ARDS. In our analysis, obesity was associated with a decreased incidence and adjusted odds for in-hospital mortality after surgery. Our results support the emerging concept of the "obesity paradox." Memtsoudis Stavros G SG Department of Anesthesiology, Hospital for Special Surgery, New York, NY 10021, USA. MemtsoudisS@hass.edu Bombardieri Anna Maria AM Ma Yan Y Walz J Matthias JM Chiu Ya Lin YL Mazumdar Madhu M eng RFA-HS-05-14 HS AHRQ HHS United States UL1 RR024996 RR NCRR NIH HHS United States UL1-RR024996 RR NCRR NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. 2011 07 21

United States J Intensive Care Med 8610344 0885-0666 IM Adult Aged Female Hospital Mortality Humans Logistic Models Male Middle Aged Multivariate Analysis Obesity complications Regression Analysis Respiratory Distress Syndrome, Adult mortality surgery Respiratory Insufficiency mortality surgery Surgical Procedures, Operative adverse effects 2011 7 21 2011 7 23 6 0 2011 7 23 6 0 2013 1 18 6 0 ppublish 0885066611411410 10.1177/0885066611411410 21778465 21301391 2012 01 31 2012 10 15 2013 10 18

1528-1159 37 3 2012 Feb 1 Spine Comparative safety of simultaneous and staged anterior and posterior spinal surgery. 247-55 10.1097/BRS.0b013e31821350d0 Analysis of population-based national hospital discharge data collected for the Nationwide Inpatient Sample. To study perioperative outcomes of circumferential spine surgery performed on either the same or different days of the same hospitalization. Circumferential spine fusion surgery has been linked to an increased adjusted risk in perioperative morbidity and mortality compared with procedures involving only 1 site. To minimize these risks, some surgeons elect to perform the 2 components of this procedure in separate sessions during the same hospitalization. The value of this approach is uncertain. Data collected between 1998 and 2006 for the Nationwide Inpatient Sample were analyzed. Hospitalizations during which a circumferential noncervical spine fusion was performed were identified. Patients were divided into those who had their anterior and posterior portion performed on the same and those performed on different days of the same hospitalization. The prevalence of patient and health care system-related demographics was evaluated. Frequencies of procedure-related complications and mortality were determined. Multivariate regression models were created to identify whether timing of procedures was associated with an independent increase in risk for adverse events. We identified a total of 11,265 entries for circumferential spine fusion. Of those, 71.2% (8022) were operated in 1 session. Complications were more frequent among staged- versus same-day surgery patients (28.4% vs. 21.7%, P < 0.0001). The incidence of venous thrombosis and adult respiratory distress syndrome also increased among staged candidates, while the trend toward higher mortality (0.5% vs. 0.4%) did not reach significance. In the regression model, staged circumferential spine fusions were associated with a 29% increase in the odds morbidity and mortality compared with same-day procedures. Staging circumferential spine surgery procedures during the same hospitalization offers no mortality benefit and may even expose patients to increased morbidity. Passias Peter G PG Division of Spine Surgery, Department of Orthopaedic Surgery, Hospital for Special Surgery/Weill Medical College of Cornell University, New York, NY, USA. Ma Yan Y Chiu Ya Lin YL Mazumdar Madhu M Girardi Federico P FP Memtsoudis Stavros G SG eng UL1 RR024996 RR NCRR NIH HHS United States UL1 RR024996-05 RR NCRR NIH HHS United States Comparative Study Journal Article

United States Spine (Phila Pa 1976) 7610646 0362-2436 IM Spine (Phila Pa 1976). 2001 Feb 15;26(4):387-90 11224886 Spine (Phila Pa 1976). 2011 Oct 15;36(22):1867-77 20453725 J Bone Joint Surg Br. 2003 Jan;85(1):90-4 12585584 Spine (Phila Pa 1976). 1979 Jan-Feb;4(1):29-36 432713 J Chronic Dis. 1987;40(5):373-83 3558716 Spine (Phila Pa 1976). 1991 Aug;16(8):930-3 1948379 J Clin Epidemiol. 1992 Jun;45(6):613-9 1607900 Spine (Phila Pa 1976). 1992 Aug;17(8 Suppl):S310-6 1523518 Med Care. 1994 Jul;32(7):700-15 8028405 Adv Data. 1995 Jul 6;(265):1-12 10154340 Eur Spine J. 1996;5(1):56-62 8689418 J Neurosurg. 1996 Sep;85(3):438-46 8751630 Stat Methods Med Res. 1996 Sep;5(3):239-61 8931195 Clin Orthop Relat Res. 1997 Dec;(345):99-105 9418626 J Spinal Disord Tech. 2005 Feb;18 Suppl:S48-57 15699805 Spine J. 2005 May-Jun;5(3):269-76 15863083 Spine (Phila Pa 1976). 2009 Sep 15;34(20):2165-70 19713875 Anesthesiology. 2009 Dec;111(6):1206-16 19934863 J Neurosurg Spine. 2010 Feb;12(2):214-20 20121359 Spine (Phila Pa 1976). 2010 Apr 1;35(7):778-83 20228715 Spine (Phila Pa 1976). 2010 Jul 1;35(15):1454-9 20216341 J Neurosurg. 2001 Apr;94(2 Suppl):232-44 11302626 Adolescent Adult Aged Child Child, Preschool Female Humans Incidence Infant Infant, Newborn Male Middle Aged Morbidity Patient Discharge Postoperative Complications mortality Risk Factors Spinal Diseases mortality surgery Spinal Fusion adverse effects methods Young Adult NIHMS278156 PMC3134539 2011 2 9 6 0 2011 2 9 6 0 2012 10 16 6 0 ppublish 10.1097/BRS.0b013e31821350d0 21301391 PMC3134539 NIHMS278156